The Lambert Eaton Myasthenic Syndrome (LEMS) market is projected to experience significant growth in the coming years, driven by rising diagnosis rates, advancements in clinical research, and the emergence of novel therapeutic options. This rare autoimmune disorder affecting the nerve-muscle connection has seen an increase in detection due to improved diagnostic techniques. Moreover, the development of targeted therapies with higher efficacy and fewer side effects is further bolstering market growth.